<DOC>
	<DOCNO>NCT03051100</DOCNO>
	<brief_summary>The purpose study determine triplet therapy bempedoic acid ( ETC-1002 ) 180mg , ezetimibe 10mg , atorvastatin 20mg effective safe versus placebo patient elevate LDL cholesterol .</brief_summary>
	<brief_title>Evaluation Efficacy Safety Bempedoic Acid ( ETC-1002 ) 180mg , Ezetimibe 10mg , Atorvastatin 20 mg Triplet Therapy Patients With Elevated LDL-C</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Fasting LDLcholesterol 130 189 mg/dL screen follow washout LDLClowering drug nutritional supplement Men nonpregnant , nonlactating woman Sufficiently stable suitable undergo washout LDLClowering drug nutritional supplement 12 week Fasting blood triglyceride great equal 400 mg/dL Body Mass Index ( BMI ) great 50 kg/m2 History clinically significant cardiovascular disease History type 1 type 2 diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>hyperlididemia</keyword>
	<keyword>LDL</keyword>
	<keyword>cholesterol</keyword>
</DOC>